<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000634</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 165</org_study_id>
    <secondary_id>00853</secondary_id>
    <nct_id>NCT00000634</nct_id>
  </id_info>
  <brief_title>A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children</brief_title>
  <official_title>A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To generate initial information on the pharmacokinetics (blood levels) and dose&#xD;
      proportionality of nevirapine (BI-RG-587) plasma levels in HIV-infected children; to assess&#xD;
      the safety and tolerance of single rising oral doses of nevirapine in HIV-infected children;&#xD;
      and to confirm that the single doses that achieve certain plasma levels in adults achieve&#xD;
      similar levels in HIV-infected children.&#xD;
&#xD;
      Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction)&#xD;
      of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus&#xD;
      that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious&#xD;
      adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction)&#xD;
      of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus&#xD;
      that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious&#xD;
      adverse effects.&#xD;
&#xD;
      Two doses, given by mouth, are evaluated: Three patients receive the lower dose, and 7 days&#xD;
      after the third patient receives the lower dose, three additional patients receive the higher&#xD;
      dose. After dosing, blood is drawn at 1, 2, 4, 8, 24, 48, 96, 168 hours to measure blood&#xD;
      levels of the drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">June 1995</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>6</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Intravenous gammaglobulin. Pneumocystis prophylaxis according to published guidelines.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Parent or guardian must be available to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Steroid dependency.&#xD;
&#xD;
        Excluded within 1 hour before and 4 hours after study drug administration:&#xD;
&#xD;
          -  Drugs that might interfere with the absorption of study drug (H2 blockers, antacids,&#xD;
             carafate, cholestyramine).&#xD;
&#xD;
          -  Benzodiazepines.&#xD;
&#xD;
          -  Alcohol-containing substances.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Requiring supplemental oxygen.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active opportunistic or serious bacterial infection.&#xD;
&#xD;
          -  Lymphoid interstitial pneumonitis (LIP) and steroid dependent or requiring&#xD;
             supplemental oxygen or have a pretreatment pa02 &lt; 70 mm Hg.&#xD;
&#xD;
          -  Pre-existing malignancies.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT) within 7 days prior to administration of study drug.&#xD;
&#xD;
        Excluded for at least 4 weeks prior to drug administration:&#xD;
&#xD;
          -  Other approved or investigational antiretroviral agents. All other investigational&#xD;
             agents. Biologic response modifiers (e.g., interferon) or immunomodulators.&#xD;
             Immunosuppressive agents (including glucocorticoids). Coumadin and other anticoagulant&#xD;
             medications.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Red blood cell transfusion within 4 weeks of study entry.&#xD;
&#xD;
        Patients may not have the following:&#xD;
&#xD;
          -  Opportunistic or serious bacterial infection.&#xD;
&#xD;
        Zidovudine (AZT) &gt; 7 days prior to administration of study drug.&#xD;
&#xD;
        Active alcohol or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr / Biotech II</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis. 1996 Oct;174(4):713-21. doi: 10.1093/infdis/174.4.713.</citation>
    <PMID>8843207</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <keyword>Benzodiazepines</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drugs, Investigational</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

